HCPCS Level II
J7529
Mycophenolate mofetil, for suspension, oral, 5 mg
Codes near J7529
These sit next to J7529 in the CMS Level II file. All J codes
- J7524Mycophenolate mofetil, oral, 5 mg
- J7525Tacrolimus, parenteral, 5 mg
- J7526Injection, mycophenolate mofetil, 5 mg
- J7527Everolimus, oral, 0.25 mg
- J7528Mycophenolate mofetil, for suspension, oral, 100 mg
- J7530Mycophenolate mofetil (myhibbin), oral suspension, 5 mg
- J7531Prednisolone sodium phosphate, orally disintegrating tablet, 1 mg
- J7599Immunosuppressive drug, not otherwise classified
- J7601Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
- J7604Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00004-0261-29 | Cellcept Oral Susp | Genentech, Inc. | 7000 |
| 00527-5160-82 | Mycophenolate Mofetil Oral Susp | Lannett Company, Inc. | 7000 |
| 23155-0848-51 | Mycophenolate Mofetil Oral Susp | Heritage Pharmaceuticals Inc. | 7000 |
| 59651-0646-26 | Mycophenolate Mofetil Oral Susp | Aurobindo Pharma Usa, Inc. | 7000 |
| 67877-0230-22 | Mycophenolate Mofetil Oral Susp | Ascend Laboratories, LLC | 7000 |
| 72603-0751-01 | Mycophenolate Mofetil Oral Susp | Northstar Rx Llc | 7000 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.